KMT2A and leukemia: The cytotoxic effect of each compound (at 10 μM) was assessed against a leukemia cell line derived from an infant with relapsed MLL-r t(4;11) acute lymphoblastic leukemia (ALL), PER-485 [11], by resazurin reduction viability assays.